Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis

Adonis Sfera
Carolina Osorio
Nyla Jafri
Eddie Lee Diaz
Jose Campo Maldonado

The University of Texas Rio Grande Valley

Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub

Part of the Infectious Disease Commons

Recommended Citation
Sfera, Adonis, Carolina Osorio, Nyla Jafri, Eddie Lee Diaz, and Jose Campo Maldonado. “Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis.” Frontiers in Immunology 11 (June 19, 2020). https://doi.org/10.3389/fimmu.2020.01472.

This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact justin.white@utrgv.edu, william.flores01@utrgv.edu.
Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis

Adonis Sfera1, Carolina Osorio2, Nyla Jafri1, Eddie Lee Diaz1 and Jose E. Campo Maldonado3

1 Patton State Hospital, San Bernardino, CA, United States, 2 Department of Psychiatry, Loma Linda University, Loma Linda, CA, United States, 3 Department of Medicine, The University of Texas Rio Grande Valley, Edinburg, TX, United States

Severe acute respiratory syndrome coronavirus 2 has spread rapidly around the globe. However, despite its high pathogenicity and transmissibility, the severity of the associated disease, COVID-19, varies widely. While the prognosis is favorable in most patients, critical illness, manifested by respiratory distress, thromboembolism, shock, and multi-organ failure, has been reported in about 5% of cases. Several studies have associated poor COVID-19 outcomes with the exhaustion of natural killer cells and cytotoxic T cells, lymphopenia, and elevated serum levels of D-dimer. In this article, we propose a common pathophysiological denominator for these negative prognostic markers, endogenous, angiotensin II toxicity. We hypothesize that, like in avian influenza, the outlook of COVID-19 is negatively correlated with the intracellular accumulation of angiotensin II promoted by the viral blockade of its degrading enzyme receptors. In this model, upregulated angiotensin II causes premature vascular senescence, leading to dysfunctional coagulation, and immunity. We further hypothesize that angiotensin II blockers and immune checkpoint inhibitors may be salutary for COVID-19 patients with critical illness by reversing both the clotting and immune defects (Graphical Abstract).

Keywords: SARS-CoV-2, cellular senescence, angiotensin II, prognosis, critical illness, immune checkpoint inhibitors

INTRODUCTION

High transmissibility, asymptomatic carriers, and the absence of herd immunity have contributed to the rapid worldwide spread of COVID-19 disease (1, 2). Although up to 50% of the affected individuals are free of clinical manifestations, about 5% of patients display serious complications, consisting of acute respiratory distress syndrome (ARDS), thromboembolism, sepsis, and multi-organ failure, often leading to death (3, 4).

COVID-19 disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is genetically related to SARS-CoV-1, known for engendering the 2002–2003 SARS epidemic. Several studies at the time have connected this virus to severe lymphopenia, involving cytotoxic T-cells (CTCs), and natural killer (NK) cells, which are indispensable for antiviral immunity (5, 6). In addition, faulty coagulation, associated with deep venous thrombosis (DVT) and pulmonary embolism (PE), has further complicated the management of this syndrome (7). These prior findings have been replicated in relation to SARS-CoV-2 and seem to precede the development of critical illness, suggesting that defective immunity may play a major role in this disease (8–10). Indeed, as in avian influenza, the upregulation of NK cell, and CTC exhaustion
markers (EMs) has been observed (11). This is somewhat surprising, as these molecules are uncommon in acute viral infections and characterize cancer and viruses associated with chronic illness, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), or cytomegalovirus (CMV) (12). In oncology, lowering EMs with immune checkpoint inhibitors (ICIs) is an established anti-tumor therapy aimed at reinvigorating host immunity, a modality with potential benefits in COVID-19 (13).

Under normal circumstances, EMs lower immune reactions to prevent autoimmunity. However, chronic inflammation can also elicit this response by prolonged stimulation of T cell receptors (TCRs) (14). Many viruses, likely including SARS-CoV-2, exploit EM pathways to avert detection. For example, SARS-CoV-2 gains access to host cells via angiotensin-converting enzyme-2 (ACE-2) associated with the renin-angiotensin system (RAS), which, aside from regulating arterial blood pressure, plays a major role in immunity (15). In this respect, SARS-CoV-2 appears to act like avian influenza viruses H5N1 and H7N9, elevating the serum levels of angiotensin II (ANG II), interleukin-6 (IL-6), and EMs (16–20).

As viral replication is more efficient in senescent cells, many viruses, including CMV and probably SARS-CoV-2, promote this phenotype in host cells to facilitate invasion (19, 21, 22). Senescent cells are characterized by proliferation arrest and a specific secretome, senescence-associated secretory phenotype (SASP). This is marked by upregulated IL-6 and reactive oxygen species (ROS), which were also detected in COVID-19 disease (23). Indeed, SARS-CoV-2 has been associated with upregulation of ANG II, a molecule previously shown to promote senescence in vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) (24–26).

We hypothesize that vascular senescence-mediated upregulation of IL-6 and ROS is responsible for both coagulation and immune dysfunction. Furthermore, this pathology, evidenced by the elevated plasma levels of EMs and D-dimer, heralds a poor COVID-19 prognosis (27). We further hypothesize that ICIs and angiotensin II blockers may help critically ill COVID-19 patients by reversing the virus-induced premature vascular senescence.
A BRIEF PATHOPHYSIOLOGY OF COVID-19 DISEASE

The SARS-CoV-2 virus gains access to host cells by engaging ACE-2 proteins, which are abundantly expressed in many tissues, including alveolar epithelial cells type II (AEC II), intestinal epithelial cells (IECs), and ECs (26, 28, 29). Interestingly, these cells function as “non-professional” antigen-presenting cells (APCs), so viral invasion directly affects their immune function. It has been established that viruses often evade detection by exploiting immunity-related host receptors. For example, the human poliovirus enters host cells via CD155, which is a receptor for T-cell immunoglobulin and ITIM domains (TIGIT) and an EM associated with functional downregulation of the CTCs and NK cells (30). Human immunodeficiency virus (HIV) upregulates EMs by maintaining a constant low-grade inflammation that repeatedly stimulates TCRs, “desensitizing” them (31). Other examples of virus-induced cellular senescence or EM upregulation are hepatitis C virus (HCV) and cytomegalovirus (CMV) (21, 32).

ACE-2 Downregulation and Critical Illness

In SARS-CoV-1 or SARS-CoV-2 infection, unfavorable prognosis has been associated with ACE-2 downregulation (33). This is a surprising and counterintuitive finding, as fewer viral entry portals should improve the clinical outcome. However, novel studies have shown that decreased levels of ACE-2 proteins cause higher illness severity and more end-organ damage (34) (Figure 1).

On closer scrutiny, ACE-2 downregulation takes place as these proteins are shed (along with the attached virus) from the cell membranes and are spread by circulation throughout the body. This occurs as SARS-CoV-2 spike (S) protein engages ACE-2 by usurping two host proteases: type II transmembrane serine protease (TMPRSS2), which facilitates viral ingress (by cleaving the S antigen into S1, the active binding site), and ADAM17, which downregulates ACE-2 proteins (by shedding them together with the attached virus) (33–37). For this reason, the latter, responsible for COVID-19 complications and end-organ damage, may be more harmful to the host (Figure 1). Indeed, since the origination of this pandemic, the research focus has been on blocking TMPRSS2 to prevent viral entry, rather than ADAM17 inhibition to avert critical illness (26).

SARS-CoV-2 and Cellular Senescence

Under normal circumstances, ACE-2 terminates the action of angiotensin (ANG I), and ANG II by cleaving these peptides into ANG 1-9 and ANG 1-7, respectively (Figure 2). In the absence of ACE-2 (due to viral blockade and downregulation), both ANG I and ANG II accumulate. However, as ACE-1 is not engaged by the virus, the conversion of ANG I to ANG II continues unabated, leading to the unopposed accumulation of ANG II. Excess ANG II has been associated with mitochondrial oxidative damage and ROS and IL-6 upregulation, impairing both coagulation and immunity (38) (Figure 2). SARS-CoV-2 may induce vascular aging and EC senescence by two mechanisms: ADAM-17 activation and NO depletion (27, 39) (Figure 2).

Indeed, preclinical studies have shown that ANG II-infused rodents demonstrated mitochondrial loss and muscle atrophy, suggesting that ANG II acts as a mitochondrial toxin (40). Taken together, SARS-CoV-2 triggers premature cellular senescence and possibly organismal aging by damaging mitochondria (41, 42).

To ARB or Not To ARB?

A controversy involving two antihypertensive drug categories, angiotensin receptor blockers (ARBs), and angiotensin converting enzyme inhibitors (ACEI), arose as a recent paper opined that these agents might upregulate ACE-2, increasing the likelihood of viral infiltration (43). However, others have found these agents not to be harmful to COVID-19 patients and possibly to be beneficial, supporting the hypothesis presented here (44–46).

Taken together, the S1/ACE-2 attachment occupies and downregulates ACE-2 proteins, rendering them incapable of cleaving ANG II, contributing to its accumulation (Figure 2).
ENDOTHELIAL SENESCENCE: ANGIOTENSIN II AND SARS-CoV-2 CRITICAL ILLNESS

Under normal circumstances, ECs are facultative APCs that synthesize tissue factors and thrombin inhibitors, maintaining both coagulation and immune homeostasis (27, 47). Although SARS-CoV-2 primarily targets AEC II in the lower respiratory tract, these cells are in close proximity to the underlying endothelium, which is likely to be infected (48). Indeed, body-wide EC damage has been reported in COVID-19, suggesting that the spread of this disease outside the respiratory system is a common occurrence (49). In addition, in COVID-19, like in HIV infection, the elevated serum D-dimer levels were found to herald a higher mortality rate, linking disease severity to impaired endothelia and coagulation (50, 51). Moreover, a recent COVID-19 study found a negative correlation between D-dimer and the number of CTCs and NK cells, connecting dysfunctional coagulation with lymphopenia (52–54).

SARS-CoV-2 and Mitochondrial Damage

Viral replication is more effective in senescent cells, and many viruses, including influenza, have been shown to promote this phenotype in their hosts (19, 22). Indeed, the H7N9 Influenza virus induces host vascular senescence by upregulating ANG II and its signaling via AT-1Rs, causing NO depletion (19, 35, 55–59) (Figure 3). As SARS-CoV-2 is believed to utilize the same mechanism, AT-1R blockers, including losartan, are currently in COVID-19 clinical trials (NCT04335123, NCT04312009, and NCT04311177) (Figure 3).

Several viruses, including polio, HIV, and SARS-CoV-1, induce senescence in host cells by inflicting mitochondrial damage (60–62). For example, the avian influenza H5N1 virus was demonstrated to impair mitochondrial antiviral signaling (MAVS) protein, inhibiting interferon release (63, 64). Since MAVS is indispensable for NK cell and CTC maturation and metabolism, disabling these proteins translates into impaired immunity (65, 66). Aside from altering MAVS, viruses can also lower host immunity by interfering with mitochondrial metabolism. Because NK and CTCs undergo metabolic rewiring to support clonal expansion and effector function upon antigen contact, viral interference with this process impairs immune responses (67). Moreover, ROSs released by the virus-damaged mitochondria not only impair NO synthesis but also activate ADAM 17, causing EC senescence by two distinct mechanisms (27, 39, 68, 69). For this reason, ADAM17 inhibitors, deemed effective against SARS-CoV-1, should be investigated against SARS-CoV-2 (35).

Angiotensin II, a Mitochondrial Toxin

In COVID-19 patients, elevated serum levels of ANG II were found to be directly correlated with viral load and the severity of
FIGURE 3 | SARS-CoV-2 engagement of ACE-2 blocks ANG II breakdown into ANG 1-7, increasing intracellular ANG II. ANG II signaling via angiotensin 1 receptors (AT-1Rs) (inhibited by ARBs), induces EC senescence and upregulates IL-6 and ROS, causing immune, and coagulation dysfunction. When ACE-2 is bound by the virus, the SARS-CoV-2/ACE-2 complexes enter host cells by endocytosis. Complexes that are not endocytosed are shed by ADAM17, contributing to critical illness.

Sfera et al. SARS-CoV-2 Clinical Prognostic Markers

**Hypothesis- Putting It All Together**

In light of the above discussion, we hypothesize the following:

1. **ANG II is a mitochondrial toxin that, under normal circumstances, is rapidly removed by ACE-2, which converts it into ANG 1-7.**

In favor of this statement, we point to several studies showing that in the absence of hydrolyzing enzyme, ACE-2, ANG II accumulates intracellularly, inducing mitochondrial elimination or damage throughout the body endothelia (36, 75–77).

2. **ACE-2 proteins are both occupied and downregulated by the SARS-CoV-2 virus and are therefore incapable of hydrolyzing ANG II.**

In favor of this assertion, we cite studies reporting that the SARS-CoV-2 receptor-binding domain (RBD) exhibits significantly higher affinity for ACE-2 and a higher degree of ACE-2 downregulation compared to the related SARS-CoV-1 (78, 79).

3. **The attachment of SARS-CoV-2 to ACE-2 is positively correlated with ANG II accumulation and negatively correlated with ACE-2 levels.**

In favor of this statement are novel findings showing that ANG II serum levels are positively correlated with both the SARS-CoV-2 viral load and lung injuries (70, 71). In addition, the density of ACE-2 protein has been found to be negatively correlated with COVID-19 critical illness (72).

4. **Excess ANG II promotes premature EC senescence along with dysfunctional coagulation and immunity.**

Several COVID-19 studies have associated poor disease prognosis with ANG II-induced endothelial dysfunction, impaired coagulation, and the overexpression of EMs (8, 27, 78, 80).

5. **SARS-CoV-2-mediated ANG II accumulation causes IL-6 and ROS upregulation, damaging the endothelia.**

Novel studies have associated SARS-CoV-2 infection with elevation of IL-6, a cytokine that inhibits endothelial NO synthesis, causing senescence (81, 82). On the other hand, IL-6-blocking antibodies are currently in clinical trials for COVID-19 (clinical trial identifier NCT04322773). Moreover, ROS upregulate ADAM17 and lower NO, triggering vascular aging (27, 39, 68, 69). Conversely, ROS scavengers, including camostat mesylate and anti-inflammatory/antioxidant supplements, are currently in COVID-19 clinical trials (clinical trial identifiers NCT04321096 and NCT04323228).

6. **Immune checkpoint inhibitors and ANG II blockers may help critically ill COVID-19 patients by reversing premature vascular senescence, restoring immune homeostasis.**

We base this assertion on novel studies showing beneficial effects of rhACE-2 and ARBs, including losartan, in SARS-CoV-2 patients. Losartan and rhACE-2 clinical trials are listed.
above (83, 84). Moreover, cancer patients with SARS-CoV-2 who were undergoing immunotherapy were found to have a better COVID-19 prognosis than those on chemotherapy, suggesting that ICIs may be helpful against SARS-CoV-2 (85). Furthermore, the clinical trial "Personalized Immunotherapy for SARS-CoV-2 (COVID-19) Associated with Organ Dysfunction (ESCAPE)" (clinical trial identifier NCT04339712) is currently assessing the potential benefit of these agents against COVID-19.

In the remaining sections of this article, we look through the prism of this pathophysiological hypothesis, attempting to identify new target molecules, or pathways that might emerge from this model (Table 1). We also point to the neuropsychiatric manifestations of COVID-19 that, as demonstrated by prior pandemics, are often delayed and involve both movement and neurodegenerative disorders.

### TABLE 1 | Potential COVID-19 therapies based on the presented hypothesis.

| Drug category       | Mechanism                                      | References/clinical trials |
|---------------------|------------------------------------------------|---------------------------|
| ADAM17 inhibitors   | Blocks ACE-2 downregulation                    | (39)                      |
| Modified polio vaccine | Lowers CD155 and TIGIT                      | (86)                      |
| Aspirin             | Lowers TIGIT                                   | (87)                      |
| Anti-TIGIT antibodies | Lower TIGIT                                   | (88)                      |
| Cariprazine         | Reinvigorate immunity                         | None                      |
| IL-6 antibodies     | Lower chronic inflammation                    | NCT04322773               |
| ROS scavengers      | Lower chronic inflammation                    | NCT04321096 and NCT04323228 |
| BCG vaccine         | Activates M1 macrophages                      | NCT04328441 and NCT04327206 |

**TIGIT: IN THE EYE OF THE “CYTOKINE STORMS”**

COVID-19 patients may present with a wide variety of immune and inflammatory responses, ranging from hyperinflammation or “cytokine storms” to immune suppression or exhaustion (89, 90). This has raised a clinical dilemma: should immunity be augmented or lowered in COVID-19 patients? Indeed, it appears that some individuals require anti-inflammatory drugs, while others are in need of immune activators (91, 92). Along these lines, both NK cells and anti-inflammatory agents are currently in COVID-19 clinical trials, indicating that both categories may be called upon due to the fact that individual immune responses to this virus can be highly variable (NCT04375176, NCT04329650). On the one hand, the SARS-CoV-2 virus likely averts detection by inducing immune disruption, while on the other, the host may unleash excessive inflammation to limit viral infection. Since human CTCs and NK cells possess a functional RAS, the virus-induced immune impairments may be mediated by this system (93). Indeed, preclinical studies have found that ARBs, including losartan, can prevent COVID-19 pulmonary injuries, suggesting that ANG II/AT-1R signaling drives the immune defects associated with SARS-CoV-2 (70). Moreover, as the TIGIT pathway has been found to promote immune dysregulation in response to many viral infections, it is likely that SARS-CoV-2 may manipulate this EM to evade detection (10). Indeed, elevated levels of IL-10, a TIGIT-signaling cytokine, have been documented in COVID-19 patients, suggesting that SARS-CoV-2 exploits these proteins to cover its molecular signatures (Figure 4) (94).

Viruses often bind to cell membrane receptors associated with immune suppression or senescence to achieve both host cell entry and a progeny-permissive microenvironment. For example, the
human poliovirus attaches to CD155, the TIGIT receptor, to upregulate this EM and inhibit host immunity (95) (Figure 4). As CD155 is associated with other immune-suppressing proteins, including CD95 and CD112 and its receptor (CD112R), it is likely that an immune inhibitory network exists around CD155 that can be exploited by viral agents to avert detection (Figure 4). For example, alpha herpesvirus targets CD112, which controls the expression of interferon gamma (IFNγ), while influenza virus induces CTC apoptosis via CD95 (96, 97) (Figure 4). Moreover, recent studies have reported that CD112R functions as a human EMs, suggesting that along with TIGIT, it may be responsible for many viral infections, including SARS-CoV-2 (98). On the other hand, TIGIT competes for CD155 binding with CD226, a receptor associated with the hyperinflammation of autoimmune disorders, suggesting the existence of a host-driven “cytokine storms” axis opposed to the virally induced immune suppressant, TIGIT (30, 99) (Figure 4). Indeed, it was recently reported that individuals expressing the CD226 G allele (which binds to CD155 with higher affinity) exhibited severe influenza symptoms, linking this gene to critical COVID-19 illness (100).

Taken together, the TIGIT–CD155–CD226 axis likely comprises a major immune switch usurped by many viruses, likely including SARS-CoV-2, to avert host detection (30, 99). As elevated serum levels of TIGIT and IL-10 have been documented in SARS-CoV-2 infection, the attenuated polio vaccine may be beneficial against COVID-19, as it inhibits CD155 and its immunosuppressive network (Figure 4).

Older Individuals and COVID-19 Critical Illness

The COVID-19 pandemic appears to affect the elderly more than children or younger adults, suggesting that immune senescence may play a role in its pathogenesis (101–103). Since ANG II/AT-1R signaling triggers immune exhaustion, older COVID-19 patients may present with more complex immune defects engendered by the simultaneous expression of exhaustion and senescence markers (104). Indeed, novel preclinical studies have demonstrated that TIGIT knockdown can reverse premature cellular and immune aging, suggesting that downregulation of this molecule may benefit COVID-19 patients (105).

Aside from older individuals, persons with higher levels of pro-inflammatory cytokines, including those with obesity and diabetes, may be at higher risk of TIGIT overexpression and COVID-19 complications. Indeed, SARS-CoV-2 critical illness is more prevalent in individuals with these conditions, as reported by the Louisiana Department of Health Update from 3/27/2020 (106) (http://ldh.la.gov/index.cfm/newsroom/detail/5517).

It is therefore possible that in individuals predisposed to autoimmunity, such as those expressing the CD226 G allele, SARS-CoV-2 may tilt the immune balance toward CD155–CD226 interaction, generating “cytokine storms.” On the other hand, in persons with preexisting immune defects, such as immune senescence, the CD155–TIGIT interaction may be enabled, engendering more profound immune deficits (by adding immune exhaustion to the previously aged CTCs and NK cells) (107, 108). Indeed, immune senescence appears to be the likely cause of the lower prevalence of autoimmune diseases and poorer response to vaccines in the elderly population (109, 110). For this reason, we surmise that the unfavorable COVID-19 prognosis is directly correlated with plasma TIGIT levels and that anti-TIGIT monoclonal antibodies could be salutary for COVID-19 patients (Figures 4, 5). Furthermore, as recombinant polio vaccines were reported to provide suitable vector systems for antigen attachment, connecting viral S protein to this vector may expedite the development of a SARS-CoV-2 vaccine (111).

THE VIRUS, THE RAS, AND THE DAS

Aside from expressing an RAS, immune cells, including dendritic cells (DC), CTCs, and NK cells, also possess a viable dopaminergic system (DAS) that plays a major role in the crosstalk between immunity and the brain (112). While the central nervous system (CNS) DAS is adequately elucidated, the role of dopamine (DA) in peripheral immunity has been less emphasized. Moreover, although a local RAS with a role in aging and cognition has previously been described in the brain, its interaction with DAS is an emerging topic in neurodegeneration, especially Parkinson’s disease (PD) (113).

Nearly 40% of COVID-19 patients present with neuropsychiatric symptoms, suggesting that this virus, like many previous pandemic-related viruses, may be neurotropic (114). Indeed, delirium, seizures, impaired consciousness, and acute cerebrovascular disease have already been described in COVID-19 patients, suggesting that SARS-CoV-2 possesses the capability of altering brain functions (114, 115). Interestingly, previous studies have associated elevated D-1mier levels with strokes and delirium, indicating that, aside from the peripheral involvement, this molecule may be the herald of unfavorable neuropsychiatric outcome in COVID-19 patients (116, 118).

Aside from entering the CNS via ANG II/AT-1Rs-related senescent endothelia, SARS-CoV-2 may access the brain directly via the cribriform plate, possibly explaining the anosmia symptom described by many COVID-19 patients (119). In addition, as influenza A virus utilizes the same entry portal and lowers local immunity by inducing the nasal expression of indoleamine 2,3-dioxygenase (IDO), SARS-CoV-2 may employ a similar mechanism (120). Furthermore, IDO inhibitors, an emerging cancer therapy, may be beneficial for the neuropsychiatric manifestations of SARS-CoV-2.

Upon CNS arrival, the virus likely blocks astrocytic and neuronal ACE-2, elevating ANG II levels. In this regard, several studies have linked excessive brain ANG II to premature neuronal aging and Alzheimer’s disease (AD) (120). Conversely, longevity was associated with the suppression of this molecule (121). Indeed, ARBs and ACEi were found to be protective against both PD and AD, indicating that RAS may play a key role in neurodegeneration (122–124). Moreover, in 2017, the US Food and Drug Administration approved a synthetic form of human angiotensin II, Giapreza, for the treatment of septic shock. The listed adverse effects of this compound include delirium, thrombotic events, and infection, resembling the central SARS-CoV-2 manifestations. Since ANG II accumulation
may be essential for COVID-19 pathogenesis, Giapreza should probably be avoided in SARS-CoV-2-associated septic shock (113, 117, 125).

A growing body of evidence has demonstrated that DA mediates the crosstalk between immunity and the CNS, suggesting that RAS, and DAS signaling may be responsible for both peripheral and central COVID-19 manifestations. Indeed, since, at the body periphery, DA alters the activation of CTCs and NK cells, it is not surprising that DA blockers are capable of inhibiting the replication of several viruses (126–129). For example, the antiviral properties of chlorpromazine have been well-documented, as this compound protects against viral entry, preventing the exploitation of immune cells (130, 131). For these reasons, we believe that patients taking antipsychotic medications may be, at least partially, protected against COVID-19, as suggested by the emerging data on forensic inpatients (unpublished research). Moreover, as reinvigoration of CTCs can be achieved by blocking dopamine D3 receptors in DCs, selective D3 partial agonists, such as cariprazine, should be assessed for COVID-19 efficacy (132). Finally, the link between excessive DA and immune defects is further substantiated by the fact that methamphetamine (METH) users with chronically elevated DA levels often present with lymphopenia as well as CTC and NK cell dysfunction (133–135). For these reasons, METH users are probably at high risk of developing SARS-CoV-2 complications. Moreover, METH was found to augment brain ANG II/AT-1R signaling, promoting neuronal senescence, and neurocognitive deficits, further emphasizing the connection between RAS and DAS in both neurodegenerative and addictive disorders (136, 137). Conversely, ARBs are currently being tested for METH addiction, as preclinical studies have reported decreased self-administration of this stimulant in candesartan-treated rodents (138). This points to the fact that a better understanding of COVID-19 may have unintended consequences: improved treatment of addictions.

Taken together, the synergistic actions of ANG II and METH illustrate the intertwined role of RAS and DAS in both COVID-19 and substance use disorders, suggesting that candesartan may be the treatment of choice for COVID-19 in METH users.

**CONCLUSIONS**

SARS-CoV-2 infection has spread around the world in a short time interval, but its prognosis is variable. Since the onset of this
pandemic, there has been an overarching focus on the virus itself and less attention on host immunity. It has been said that Nature plays a cruel game of chess in which the host and pathogen can only thrive by outmaneuvering each other. Like influenza viruses, cancer, and chronic viral infections, SARS-CoV-2 evades detection by disguising itself as an ACE-2 ligand. The host responds by mobilizing its innate and adaptive immunity to eliminate the virus, but the latter proceeds to downregulate host immune defenses by augmenting EMs. In a desperate move, the host unleashes "cytokine storms" to reinvigorate its suppressed immune cells and overcome the virus. However, this extreme maneuver sacrifices the vulnerable individuals, such as those with chronic inflammation, damaged endothelia, and defective immunity. But Nature has rarely been fair to the weak, as their demise contributes to herd immunity.

And the life-death cycles go on and on, moves and countermoves, hosts and pathogens. Indeed, it has been said that man can come up with better and better mousetraps, but Nature can always build better mice.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

---

**REFERENCES**

1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. / Autoimmun. (2020) 109:102433. doi: 10.1016/j.jaut.2020.102433

2. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. (2020) 395:514–23. doi: 10.1016/S0140-6736(20)30154-9

3. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019, pneumonia in Wuhan, China. JAMA Intern Med. (2020). doi: 10.1001/jama.2020.0994. [Epub ahead of print].

4. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019. (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. (2020). 323:1329–42 doi: 10.1001/jama.2020.2648

5. Wong RS, Wu A, To KF, Nelson L, Lam CEK, Wong CK, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. (2003) 326:1358–62. doi: 10.1136/bmj.326.7403.1358

6. Oh HL, Chia A, Chang CX, Leong LN, Ling LL, Gijsbert M, et al. Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8+ T cell epitope. J Virol. (2011) 85:10464–71. doi: 10.1128/JVI.05039-11

7. Xiang-Hua Y, Le-Min W, Ai-Bin L, Zhu G, Riquan L, Xu-You Z, et al. Severe acute respiratory syndrome and venous thromboembolism in multiple organs. Am J Respir Crit Care Med. (2010) 182:426–7. doi: 10.1164/ajrccm.182.3.4346

8. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019. (COVID-19). medRxiv. (2020). doi: 10.1101/2020.02.02.20024364

9. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immuno Res. (2014) 59:118–28. doi: 10.1007/s12026-014-8534-z

10. Schorr M, Rakebrandt N, Lambert K, Hunziker A, Pallmer K, Oxenius A, et al. TIGIT limits immune pathology during viral infections. Nat Commun. (2020) 11:12288. doi:10.1038/s41467-020-15025-1

11. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. (2007) 27:670–84. doi: 10.1016/j.immuni.2007.09.006

12. Saedi A, Zandi K, Cheok YY, Saedi H, Wong WF, Yie Qin Lee C, et al. T-cell exhaustion in chronic infections: reversing the state of exhaustion and reinvigorating optimal protective immune responses. Front Immunol. (2018) 9:2569. doi: 10.3389/fimmu.2018.02569

13. Liu M, Guo F. Recent updates on cancer immunotherapy. Precis Clin Med. (2018) 1:65–74. doi: 10.1093/pcm/phy011

14. Jackson SR, Berrien-Elliot MM, Meyer JM, Wherry EJ, Teague RM. CD8+ T cell exhaustion during persistent viral infection is regulated independently of the virus-specific T cell receptor. Immuno Invest. (2013) 42:204–20. doi: 10.3109/088292013.2012.751397

15. South AM, Diz D, Chappell MC. COVID-19 ACE2 and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. (2020) 318:H1084–90. doi: 10.1152/ajpheart.00217.2020

16. Zou Z, Yan Y, Shu Y, Gao R, Sun X, Ju X, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun. (2014) 5:5394. doi: 10.1038/ncomms5394

17. Paquette SG, Banner D, Zhao Z, Fang Y, Huang SSH, et al. Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection. PLoS ONE. (2012) 7:e38214. doi: 10.1371/journal.pone.0038214

18. Rutigliano JA, Sharma S, Morris MY, John A, Ogquín TH, McClaren JL, et al. Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells. J Virol. (2014) 88:1636–51. doi: 10.1128/JVI.02851-13

19. Yan Y, Du Y, Zheng H, Wang G, Rui Li, Chen J, et al. NS1 of H7N9 influenza A virus induces NO-mediated cellular senescence in Neuro2a cells. Cell Physiol Biochem. (2017) 43:1369–80. doi: 10.1159/000481848

20. Tousoulis D, Kampoli AM, Toulouarlis C, Papageorgiou N, Stefanadis C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol. (2012) 10:4–18. doi: 10.2174/15701611279829760

21. Solana R, Tarazona R, Aiello AE, Akbar AN, Appay V, Beswick M, et al. CMV and Immunosenescence: from basics to clinics. Immun Ageing. (2012) 9:23. doi: 10.1186/1742-4933-9-23

22. Kim JA, Seong RK, Shin OS. Enhanced viral replication by cellular replicative senescence. Immune Netw. (2016) 16:286–95. doi: 10.4110/in.2016.16.5.286

23. Qudrat A, Wong J, Truong K. Engineering mammalian cells to seek senescence-associated secretory phenotypes. J Cell Sci. (2017) 130:3116–23. doi: 10.1242/jcs.206979

24. Kunieda T, Minamino T, Nishi J, Tateno K, Oyama T, Kitsumo T, et al. Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Circulation. (2006) 114:953–60. doi: 10.1161/CIRCULATIONAHA.106.626606

25. Shan H, Bui X, Chen X. Angiotensin II induces endothelial cell senescence via the activation of mitogen-activated protein kinases. Cell Biochem Funct. (2008) 26:459–66. doi: 10.1002/cbf.1467

26. Luther JM, Gainer JV, Murphey RJ, James Luther M, Gainer JV, Murphey LJ, et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension. (2006) 48:1050–7. doi: 10.1161/01.HYP.0000248135.97380.76

27. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thorbm Haemost. (2020) 18:844–7. doi: 10.1111/jth.14768
32. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narváez AB, et al. Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Physiol Lung Cell Mol Physiol. (2011) 342:143–7. doi: 10.1097/MAJ.0b013e318222e620

33. Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pöhlmann S. MHC class II expression and its role in antigen presentation in the gastrointestinal and respiratory tracts. Front Immunol. (2018) 9:2144. doi: 10.3389/fimmu.2018.02144

34. Mehra MR, Sapan, Desai S, Kuy SR, Henry TD, Patel AN. Cardiovascular angiotensin–aldosterone system blockers and the risk of COVID-19. J Infect Dis. (2020) 221:1762–9. doi: 10.1093/infdis/jiaa150

35. Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata M, et al. Senescent endothelial cells: potential modulators of immunosenescence and ageing. Ageing Res Rev. (2016) 29:13–25. doi: 10.1016/j.arr.2016.05.011

36. Brill A, Chauhan AK, Canault M, Walsh MT, Bergmeier W, Wagner DD. Mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease. Front Immunol. (2019) 10:2596. doi: 10.3389/fimmu.2019.02596

37. van Hinsbergh VW. Endothelium–role in regulation of coagulation and inflammation. Semin Immunopathol. (2012) 34:93–106. doi: 10.1007/s00281-011-0285-5

44. Mehra MR, Wang C, Tidgj J, Si X, Dumpit C, Charles S, et al. Influenza infects lung microvascular endothelium leading to microvascular leak: role of apoptosis and Claudin-5. PLoS ONE. (2012) 7:e47323. doi: 10.1371/journal.pone.0047323

47. van Hinsbergh VW. Endothelium–role in regulation of coagulation and inflammation. Semin Immunopathol. (2012) 34:93–106. doi: 10.1007/s00281-011-0285-5

48. Armstrong SM, Wang C, Tigidi J, Si X, Dumpit C, Charles S, et al. Influenza infects lung microvascular endothelium leading to microvascular leak: role of apoptosis and Claudin-5. PLoS ONE. (2012) 7:e47323. doi: 10.1371/journal.pone.0047323

49. Zhou F, Yu T, Du R, Fan G, Du R, Fan G, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3

50. Hileman CO, Longenecker CT, Carman TL, Milne GL, Labbato DE, Storer NJ, et al. Elevated D-dimer is independently associated with endothelial dysfunction: a cross-sectional study in HIV-infected adults on antiretroviral therapy. Antivir Ther. (2012) 17:1345–9. doi: 10.3851/IMP2297

51. Wan S, Xiang Y, Fang W, Zheng Y, Boqun L, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. (2020) 92:797–806. doi: 10.1002/jmv.25783

52. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. (2020) 221:1762–9. doi: 10.1093/infdis/jiaa150

53. Zheng M, Gao Y, Wang, Song GG, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. (2020) 17:533–5. doi: 10.1038/s41423-020-0402-2

54. Pantsulaiia IA, Ciszewski WM, Niewiarowska J. Senescent endothelial cells: potential modulators of immunosenescence and ageing. Ageing Res Rev. (2016) 29:13–25. doi: 10.1016/j.arr.2016.05.011

55. Yang P, Gu H, Zhao Z, Wang W, Cao B, Chengcai Lia C, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep. (2014) 4:7027. doi: 10.1038/srep07027

56. Ye S, Lowther S, Stambas J. Inhibition of reactive oxygen species production ameliorates inflammation induced by influenza A viruses via upregulation of SOCS1 and SOCS3. J Virol. (2015) 89:2672–83. doi: 10.1128/JVI.00529-14

57. Otani A, Takagi H, Oh H, Oh H, Suzuma K. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Invest Ophthalmol Vis Sci. (2000) 41:1192–9.

58. Kim CG, Jang M, Kim Y, Leem G, Kim KH, Lee H, et al. VEGF-A drives T cell-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. Sci Immunol. (2019) 4:aay0555. doi: 10.1126/sciimmunol.aay0555

59. Li YL, Zhao H, Ren XB. Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward? Cancer Biol Med. (2016) 13:206–14. doi: 10.20892/j.issn.2095-3941.2015.0070

60. Sun J, Longchamps RJ, Piggott DA, Castellani CA, Sumpter JA, Brown TT, et al. Association between HIV infection and myocardial infarction in peripheral blood: a population-based, prospective cohort study. J Infect Dis. (2019) 219:1285–93. doi: 10.1093/infdis/jiy658

61. Shi CS, Qi HY, Boulanar C, Huang NN, Abu-Asab M, Shellhammer JH, et al. SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome. J Immunol. (2014) 193:3080–9. doi: 10.4049/jimmunol.1303196

62. Yarosz EL, Chang CH. The role of reactive oxygen species in regulating T cell-mediated immunity and disease. Immune Netw. (2018) 18:e14. doi: 10.1128/IN.2018.00002

63. Bian Q, Lu J, Zhang L, Chi Li, Lu Y, Guo H. Highly pathogenic avian influenza A virus H5N1 non-structural 1 protein is associated with apoptotic activation of the intrinsic mitochondrial pathway. Exp Ther Med. (2017) 14:4041–6. doi: 10.3892/etm.2017.7506

64. Long JC, Fooler E. The PB2 subunit of the influenza A virus RNA polymerase is imported into the mitochondrial matrix. J Virol. (2016) 90:8729–38. doi: 10.1128/JVI.01384-16

65. Haynes LD, Verma S, McDonald B, Wu, R, Tacke R, Nowyheid HN, et al. Cardil (MAVS) regulates the maturation of NK cells. J Immunol. (2015) 195:2057–67. doi: 10.4049/jimmunol.1402060

66. Angaijala A, Lim S, Phillips JB, Kim J-H, Yates C, You Z, et al. Diverse roles of mitochondria in immune responses: novel insights into immune-metabolism. Front Immunol. (2018) 9:1605. doi: 10.3389/fimmu.2018.01605
80. Han H, Yang L, Liu R, Liu F, Wu KL, Li J, et al. Prominent changes in blood
81. Hung MJ, Cherng WJ, Hung MY, Wu HT, Pang JH. Interleukin-
82. Chen X, Zhao B, Qu Y, Chen Y, Xiong, J Feng JY, et al. Detectable serum
angiotensin peptides levels in acute respiratory distress syndrome correlate with clinical outcomes: a pilot study. PLoS ONE. (2019) 14:e0213096.
doi: 10.1371/journal.pone.0213096.
83. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of
84. Fisicaro P, Barili V, Montanini B, Acerbi G, Ferracin M, Guerrieri F, et al. Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat Med. (2017) 23:327–36. doi: 10.1038/nm.4275.
85. Morancho B, Martínez-Barriocanal Á, Villanueva J, Arribas J. Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence. Breast Cancer Res. (2015) 17:106. doi: 10.1186/s13058-015-0169-7.
86. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. (2020) 63:364–74. doi: 10.1007/s11430-020-1643-8.
87. Reddy R, Asante I, Liu S, Parikh P, Liebler J, Borok Z, et al. Circulating angiotensin peptides levels in acute respiratory distress syndrome correlate with clinical outcomes: a pilot study. PLoS ONE. (2019) 14:e0213096.
doi: 10.1371/journal.pone.0213096.
88. Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS, Friedman AH, et al. Recurrent globostobla treated with recombinant poliovirus. N Engl J Med. (2018) 379:150–61. doi: 10.1056/NEJMoa17 16435.
89. Bode-Böger SM, Martens-Lobenhoffer J, Tager M, Schröder H, Scala F. Aspirin reduces endothelial cell senescence. Biochem Bioph Res Comm. (2005) 334:1226–32. doi: 10.1016/j.bbrc.2005.07.014.
90. Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology. (2018) 7:e1466769. doi: 10.2126/2162402X.2018.1466769.
91. Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. (2020) 55:105982. doi: 10.1016/j.ijantimicag.2020.105982.
92. Jurewicz M, McDermott DH, Sechler JM, Timckak K, Takakura A, Carpenter CB, et al. Functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol. (2017) 28:1093–102. doi: 10.1681/ASN.2016060707.
93. Kugler R, Lo C, Zel A, Del Vecchio P, et al. The coronavirus dilemma. J. Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence. Breast Cancer Res. (2015) 17:106. doi: 10.1186/s13058-015-0169-7.
94. Ayano M, Tsukamoto H, Kohno K, Ueda N, Tanaka A, Mitoma H, et al. NK cell-mediated lysis of infected cells. J Exp Med. (2015) 213:167–76. doi: 10.1084/jem.20150785.
95. Chiappelli F, Khakshooy A, Greenberg G. CoViD-19 immunopathology and immunotherapy. Bioinformation. (2020) 16:219–22. doi: 10.6026/97320630016219.
96. van Kats JP, de Lannoy LM, Jan Danser AH, van Meegen JR, Verdouw PD, Schalekamp MA. Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension. (1997) 30:42–9. doi: 10.1161/01.HYP.30.1.42.
97. Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease (2019). (2019-2020) in cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc. (2020) 9:e016219. doi: 10.1161/JAHA.120.016219.
98. Tai W, He L, Zhang, Pe Xu, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. (2020) 17:613–20. doi: 10.1038/s41423-020-0400-4.
99. Han H, Yang Y, Liu R, Liu F, Wu KL, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. (2020). doi:10.1515/cclm-2020-0188. [Epub ahead of print].
100. Hung MJ, Cherrington, Meng C, Huang Y, Wu HT, Pang JH. Interleukin-6 inhibits endothelial nitric oxide synthase activation and increases endothelial nitric oxide synthase binding to stabilized caveolin-1 in human vascular endothelial cells. J Hypertens. (2010) 28:940–51. doi: 10.1097/HJH.0b013e32833992ef.
101. Chen X, Zhao B, Qu Y, Chen Y, Xiong, J Feng JY, et al. Detectable serum SARS-CoV-2 viral load (RNAemia) is closely associated with drastically elevated interleukin-6 (IL-6) level in critically ill COVID-19 patients. medRxiv. 2020. doi:10.1101/2020.02.29.20029520.
102. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. (2020). doi:10.1002/ddr.21656. [Epub ahead of print].
regarding pathogenesis, immune responses, and outcomes. *GeroScience.* (2020) 42:1013. doi: 10.1007/s11357-020-00193-1

103. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. *J Infect.* (2020) 80:e14–8. doi: 10.1016/j.jinf.2020.03.003

104. Crowley SD, Rudemiller NP. Immunologic Effects of the Renin-Angiotensin System. *J Am Soc Nephrol.* (2017) 28:1350–1361. doi: 10.1681/ASN.2016101066

105. Song Y, Wang B, Song R, Hao Y, Wang D, Li Y, et al. T-cell immunoglobulin and ITIM domain contributes to CD8+ T-cell immunosenescence. *Aging Cell.* (2018) 17. doi: 10.1111/acel.12716

106. Aguilar EG, Murphy WJ. Obesity induced T cell dysfunction and implications for cancer immunotherapy. *Curr Opin Immunol.* (2018) 51:181–6. doi: 10.1016/j.coi.2018.03.012

107. Pan XK, Wu F, Chen XH, Chen D-R, Chen H-J, Kong L-R, et al. T cell senescence accelerates Angiotensin II-induced target organ damage. *Cardiovasc Res.* (2020) cvaa032. doi: 10.1093/cvr/cvaa032.

108. Nakamura K, Yaguchi T, Ohmura G, Kobayashi A, Kawamura N, Iwata T, et al. Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment. *Cancer Sci.* (2018) 109:54–64. doi: 10.1111/cas.13423

109. Vadass Z, Haj T, Kessel A, Toubi E. Age-related autoimmunity. *BMCE Med.* (2013) 11:94. doi: 10.1186/1741-7015-11-94

110. Aspinni R, Del Giudice G, Effros, Grubeck-Loebenstein B, Samihara S. Challenges for vaccination in the elderly. *Immun Ageing.* (2007) 4:9. doi: 10.1186/1741-7015-4-9

111. Mandl S, Sigal LJ, Rock KL, Andino R. Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen. *Proc Natl Acad Sci USA.* (1998) 95:8216–21. doi: 10.1073/pnas.95.14.8216

112. Beck GC, Brinkkoetter P, Hanusch C, Schulte J, van Ackern K, van der Poll PF, et al. The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model. *Arch Virol.* (2020) 165:671–81. doi: 10.1007/s00705-020-05424-7

113. Jan RK, Kydd RR, Russell BR. Functional and structural brain changes associated with these terms. *Front Neurosci.* (2017) 9:129. doi: 10.3389/fnens.2017.00129

114. Guo YJ, Chang MH, Chen PL, Lee YS, Chang YC, Liao YC. Predictive value of plasma (D)-dimer levels for cancer-related stroke: a 3-year retrospective study. *J Stroke Cerebrovasc Dis.* (2014) 23:249–54. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.022

115. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. *Lancet.* (2020) 395:e52. doi: 10.1016/S0140-6736(20)30558-4

116. Khalique SC, Ferguson N. Angiotensin II (Giaprea): a distinct mechanism for the treatment of vasodialatory shock. *Cardiol Rev.* (2019) 27:167–9. doi: 10.1097/CRD.0000000000000247

117. Farina N, Bixby A, Alaniz C. Angiotensin II and T-cell immunity. *Front Immunol.* (2020) 11:929. doi: 10.3389/fimmu.2020.00979

118. Cooper HA, Scala R, Rizzo V, Eguchi S. Angiotensin II- and alzheimer-type cardiovascular aging. *Circ Res.* (2018) 123:651–3. doi: 10.1161/CIRCRESAHA.118.313477

119. Casisi P, Conti S, Remuzzi G, Benigni A. Angiotensin receptors as determinants of life span. *Pflugers Arch.* (2010) 459:325–32. doi: 10.1007/s00424-009-0725-4

120. Perez-Lloret S, Officer-Losada M, Toblli JE, Capani F. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease. *Expert Opin Investig Drugs.* (2017) 26:1163–73. doi: 10.1080/13543784.2017.1371133

121. Ho JK, Nation, DA. Memory is preserved in older adults taking AT1 receptor blockers. *Alz Res Therapy.* (2017) 9:33. doi: 10.1186/s13195-017-0255-9

122. Lee YC, Lin CH, Wu RM, Lin JW, Chang CH, Lai MS. Anti hypertensive agents and risk of Parkinson’s disease: a nationwide cohort study. *PLoS ONE.* (2014) 9:e99861. doi: 10.1371/journal.pone.0099861

123. Biancardi VC, Stern JE. Compromised blood-brain barrier permeability: novel mechanism by which circulating angiotensin II signals to sympathoexcitatory centres during hypertension. *J Physiol.* (2016) 594:1591–600. doi: 10.1113/JP271584

124. Simonjuntak Y, Li, Lee YL, Lin YL. Japanese encephalitis virus exploits dopamine D2 receptor-phospholipase C to target dopaminergic human neuronal cells. *Front Microbiol.* (2017) 8:651. doi: 10.3389/fmicb.2017.00651

125. de Oliveira LC, Ribeiro AM, Albaranz JDS, Torres AA, Guimarães LFZ, Pinto AK, et al. The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model. *Arch Virol.* (2020) 165:671–81. doi: 10.1007/s00705-020-05424-7

Copyright © 2020 Sfera, Osorio, Jafri, Diaz and Campo Maldonado. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practices. No use, distribution or reproduction is permitted which does not comply with these terms.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.